[go: up one dir, main page]

Mehta, 2006 - Google Patents

Amyloid beta and tau proteins in

Mehta, 2006

Document ID
56125212916030398
Author
Mehta P
Publication year
Publication venue
Down Syndrome and Alzheimer's Disease: Biological Correlates

External Links

Snippet

Alzheimer's disease (AD) is one of the commonest dementing illnesses, affecting about four million people in the USA. It is characterised clinically not only by an impairment in cognition but also by a decline in global function, a deterioration in the ability to perform activities of …
Continue reading at books.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Similar Documents

Publication Publication Date Title
Frank et al. Biological markers for therapeutic trials in Alzheimer’s disease: proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease
Blennow et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Ronald et al. Consensus report of the working group on:“Molecular and biochemical markers of Alzheimer’s disease”
Rosenmann CSF biomarkers for amyloid and tau pathology in Alzheimer's disease
Mollenhauer et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
JP4580455B2 (en) Differential diagnosis of neurodegeneration
US6680173B2 (en) Diagnosis of tauopathies
Davies et al. Consensus report of the Working Group on:" Molecular and Biochemical Markers of Alzheimer's Disease"
Andreasen et al. β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Maccioni et al. Biological markers of Alzheimer's disease and mild cognitive impairment
JP2015505365A (en) Methods for diagnosing Alzheimer's disease
US20040014142A1 (en) Differential diagnosis of neurodegeneration
Cattabeni et al. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease
Mehta Amyloid beta protein as a marker or risk factor of Alzheimer's disease
EP2997379B1 (en) Method for in vitro diagnosis of a neurological disorder
Mehta et al. Biological markers of Alzheimer's disease
Mehta Amyloid beta and tau proteins in Alzheimer’s disease and Down syndrome
Hampel et al. Biomarkers in blood and cerebrospinal fluid
Mehta Amyloid beta and tau proteins in
Paterson et al. Biomarker modelling of early molecular changes in Alzheimer’s disease
US9618522B2 (en) Diagnostic testing in dementia and methods related thereto
Zetterberg et al. Cerebrospinal fluid biomarkers in Alzheimer’s Disease
Schoonenboom et al. Cerebrospinal fluid markers for the diagnosis of Alzheimer’s disease
Hirota et al. Short title p-tau biomarkers represent Aβ pathology
Van de Voorde et al. 4 Combination of tau/phospho-tau with other biochemical markers to improve the specificity of an Alzheimer's disease test